 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...6789101112131415161718» |
- fludarabine / Generic mfg., Leukeran (chlorambucil) / GSK
Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2581;
Taken together, these data identify rs736456 and rs3778076 as prognostic in early stage CLL patients demonstrating that progression of CLL from asymptomatic to symptomatic disease is determined by constitutional genetic variation as well as the more established somatic drivers. Constitutional genetic markers have the advantage of being easy to perform, highly reproducible and inexpensive making them ideal for incorporation into multivariate prognostication models for early stage CLL.
- Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2580;
The mechanism for this may, in part, via activated ERK and c-Jun levels (Figure1). We believe that these changes in both molecules are associated with leukemic B-cell survival and drug resistance (Figure1).
- Rituxan (rituximab) / Roche, Biogen
An Analysis from the WM UK Rory Morrison Registry - How Does Waldenström’s Macroglobulinemia Affect Younger Patients? (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2373;
Encouragingly, OS rates are generally good, although a high IPSSWM risk carries a markedly lower 5-year OS rate also in the younger cohort. A more detailed analysis is underway to explore these issues further.
- Rituxan (rituximab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study (W308, Level 3 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_1639;
Despite high OOP costs, the use of first-line ibrutinib is not associated with sociodemographic characteristics, suggesting that therapeutic decisions are determined by clinical factors. The real-world survival of older patients on ibrutinib is poorer than seen in clinical trials, and rates of AFib, VArr and CNSh are higher.
- Venclexta (venetoclax) / Roche, AbbVie, Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial (Hall D, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_1317;
Findings confirm the prognostic value of MRD assessment at EOT for this chemotherapy-free treatment regimen . Due to high concordance of undetectable MRD in PB and BM in the context of VenG, BM assessments may not be required for these patients.
- Gazyva (obinutuzumab) / Biogen, Roche, Calquence (acalabrutinib) / AstraZeneca
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (Hall D, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_1312;
P3
Acalabrutinib + O and acalabrutinib monotherapy significantly improved PFS vs O + Clb, with tolerable safety in pts with TN CLL . Despite cross over for disease progression in the O + Clb arm, a trend toward improved OS was observed in both acalabrutinib arms, though longer follow-up is needed.
- cyclophosphamide intravenous / Generic Mfg.
Polyphenols Enhance the Activity of Alkylating Agents in Leukaemia Cell Lines () - Nov 5, 2019 - Abstract #NCRI2019NCRI_339;
Similarly, apigenin and rhein acted synergistically when combined with chlorambucil in lymphoid leukaemia cell lines. In myeloid leukaemia cell lines, all three alkylating agents had differential effects.
- | Leukeran (chlorambucil) / GSK
Preclinical, Journal: Type III-C rotaxane dendrimers: synthesis, dual size modulation and in vivo evaluation. (Pubmed Central) - Oct 25, 2019
The biological distribution of dendrimers in C57BL/6J mice determined by MALDI-TOF-MS shows predominant accumulation in the spleen and liver. Drug encapsulations with chlorambucil and lithocholic acid were demonstrated.
- tacrolimus / Generic Mfg., Rituxan (rituximab) / Roche, Biogen
LONG-TERM USE OF RITUXIMAB IN DIFFICULT-TO -TREAT HISPANIC CHILDREN WITH NEPHROTIC SYNDROME () - Oct 25, 2019 - Abstract #IPNA2019IPNA_18;
SRNS patients had failed to respond to prednisone and additional 2 (2 – 4) immunosuppressants... Long-term use of rituximab is effective and safe in children with difficult-to-treat NS, including SRNS who have failed to respond to multiple immunosuppressants.
- Rituxan (rituximab) / Roche, Biogen
New drugs for CLL () - Oct 23, 2019 - Abstract #EHOC2019EHOC_3;
P1/2
LIkewise, a loinger PFS was observed in the ibrutinib arms in 2 trials comparing ibrutinib with bendamustine and rituximab or chlorambucil and obinutuzumab [5,6]...The phase 3 RESONATE trial compared single-agent ibrutinib to ofatumumab in 391 patients with relapsed/refractory CLL (ibrutinib n=195, ofatumumab n=196) with a median age of 67 (≥70 40% and 41% in the two group respectively) [7]...This is a randomized, multicenter, open-label phase 3 trial which evaluated efficacy and safety of acalabrutinib monotherapy vs investigator choice therapy (Rituximab plus Idelalisib or Bendamustine) in R/R CLL...In a phase 2 trial [20] ibrutinib was combined with fludarabine, cyclophosphamide and obinutuzumab (iFCG) 32 previously untreated CLL patients with M-IGHV and without TP53 disruption received this combination...The long-term experience with ibrutinib single agent until progression is very positive and fixed duration treatment with venetoclax and rituximab is a new paradigm for treatment of CLL. Combination treatment (CIT + ibrutinib or venetoclax combined with ibrutinib) are very promising regimens.
- Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Oncology Nursing Experience in Phase 3 iLLUMINATE: First-Line Ibrutinib-Obinutuzumab Versus Chlorambucil-Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) () - Oct 20, 2019 - Abstract #AONNNSC2019AONN_NSC_106;
P3
First-line combination therapy with ibrutinib-obinutuzumab represents an effective chemotherapy-free regimen for patients with CLL and is associated with significantly improved PFS and fewer IRRs versus chlorambucil-obinutuzumab. Oncology nurses play critical roles in educating patients, monitoring AEs, and supporting the management of patients receiving continuous ibrutinib therapy to help achieve maximal treatment benefit.
- cyclophosphamide intravenous / generics
Early vs. Late Start of Immunosuppressive Therapy in Membranous Nephropathy (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_3007;
Our data support the safety of a delayed treatment strategy. Baseline characteristics and outcomeMean±SD, Median [IQR]FundingGovernment Support - Non-U.S.
- | Gazyva (obinutuzumab) / Biogen, Roche
Clinical, P3 data, Journal: Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. (Pubmed Central) - Oct 11, 2019
P3
Safety data were consistent with previous reports, and response rates were high. Clinicaltrials.gov identifier: NCT01905943.
- Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: up to 4 years of extended follow-up from phase 3 ILLUMINATE () - Oct 9, 2019 - Abstract #iwCLL2019IWCLL_47;
- Leukeran (chlorambucil) / GSK, Imbruvica (ibrutinib) / AbbVie, J&J
Real-life retrospective comparison of chlorambucil plus anti-CD20 antibody versus ibrutinib alone as frontline treatment for unfit CLL/SLL () - Oct 9, 2019 - Abstract #iwCLL2019IWCLL_43;
- Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Feasibility of obinutuzumab (G) combined with higher doses of chlorambucil (Clb) for frontline treatment of CLL: a retrospective noninterventional study of KroHem, the Croatian Cooperative Group for Hematologic Diseases () - Oct 9, 2019 - Abstract #iwCLL2019IWCLL_33;
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus bendamustine and rituximab plus chlorambucil in front-line CLL therapy: The GO-CLLEAR Study by Czech CLL Study Group () - Oct 9, 2019 - Abstract #iwCLL2019IWCLL_18;
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche, Rituxan (rituximab) / Roche, Biogen
Clinical, Journal: Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. (Pubmed Central) - Oct 8, 2019
Clinicaltrials.gov identifier: NCT01905943. No abstract available
- | tacrolimus / Generic Mfg.
Clinical, Journal: Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy. (Pubmed Central) - Oct 7, 2019
On the third day of treatment, a severe decrease in diuresis and kidney function occurred and CsA was discontinued, resulting in a return to baseline kidney function. After 2 months, the situation repeated after attempting to introduce tacrolimus.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, cyclophosphamide intravenous / Generic Mfg., Rituxan (rituximab) / Roche, Biogen
Adult Primary Central Nervous System Vasculitis Treatment and Course: A Long-term Follow-up Study (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_2770;
Cerebral infarctions at diagnosis were associated with poor response to treatment and worst outcomes. MMF and RTX appears to be effective therapy for PCNSV.
- | melphalan / Generic Mfg., Leukeran (chlorambucil) / GSK
Journal: Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. (Pubmed Central) - Oct 2, 2019
The introduction of an amino acid side chain improved the solubility and permeability of 10. Furthermore, 10 inhibited the growth of TNBC tumors of xenografted mice without obvious signs of general toxicity making this compound an ideal drug candidate for clinical development.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Trial termination: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Oct 1, 2019
P1, N=38, Terminated, Sponsor: Hoffmann-La Roche
Furthermore, 10 inhibited the growth of TNBC tumors of xenografted mice without obvious signs of general toxicity making this compound an ideal drug candidate for clinical development. Completed --> Terminated; This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 1, 2019
P3, N=445, Active, not recruiting, Sponsor: Hoffmann-La Roche
Completed --> Terminated; This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR. Trial completion date: Sep 2021 --> Sep 2020
- bleomycin / Generic Mfg., BMS, Leukeran (chlorambucil) / GSK, Imbruvica (ibrutinib) / AbbVie, J&J
Chronic lymphocytic leukemia judge syndrome in a Hodgkinlymphom (A6) - Sep 30, 2019 - Abstract #DGHO2019DGHO_1407;
Only 0.4-0.7% of CLL patient transformed into a M. Hodgkin.Prognostically is Hodgkin transformation better than DLBCL, but worse than de novo Hodgkin. There exists two types with different pattern of Richter transformation of CLL.
- Rituxan (rituximab) / Roche, Biogen
Autologous stem cell transplantation in first remission significantly increases progression-free and overall survival in mantle cell lymphoma (A6) - Sep 30, 2019 - Abstract #DGHO2019DGHO_1081;
However, in the subset of patients treated with rituximab there was only a non-significant trend for PFS and no difference in OS, potentially due to the reduced statistical power of this subgroup analysis. In the current study generation, the substitution of ASCT by the BTK inhibitor Ibrutinib is evaluated.
- fludarabine / Generic Mfg., Leukeran (chlorambucil) / GSK, bendamustine / SymBio, Mundipharma, Astellas, Generic Mfg.
Second cancer in treated and untreated patients with chronic lymphocytic leukemia (CLL): an analysis of the registry of the German CLL study group (DCLLSG) (M6 / M7) - Sep 30, 2019 - Abstract #DGHO2019DGHO_203;
Compared with treated patients, the incidence of SPM appears lower in untreated patients despite the higher median age in this group. This observation might suggest an influence of CLL treatment or more advanced disease stage on the occurrence of SPM.
- Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Leukeran (chlorambucil) / GSK
Cytomegalovirus and herpes simplex 2 retinitis –a rare presentation in a patient receiving obintuzumab for chronic lymphocytic leukemia () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1024;
ARN can occur in both immunocompetent and immunosuppressed individuals. It is caused by infection of the retina with HSV or herpes zoster virus.
- Imbruvica (ibrutinib) / AbbVie, J&J
Ibrutinib for Chronic Lymphocytic Leukemia (CLL): A Single Center Experience in Bogotá, Colombia (Chronic Lymphocytic Leukemia) - Sep 26, 2019 - Abstract #SOHO2019SOHO_491;
No patient discontinued treatment due to AE.Conclusions Ibrutinib has been reported to be highly effective and safe in CLL treatment. Here we report a single center experience, reproducing similar results as reported in other countries.
- Imbruvica (ibrutinib) / AbbVie, J&J
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) - Sep 26, 2019 - Abstract #SOHO2019SOHO_472;
P3
Patients responded to subsequent therapies, including chemoimmunotherapy and alternate kinase inhibitors, following ibrutinib.Conclusions Single-agent ibrutinib demonstrated sustained PFS and OS benefit with >5 years of follow up, including for patients with high-risk genomic features. Nearly three-fold more patients achieved CR/CRi, >50% of patients remain on continuous ibrutinib, and no new safety signals have emerged.Funding Pharmacyclics LLC, an AbbVie Company.
- Rituxan (rituximab) / Roche, Biogen
CLL: State of the Art Update () - Sep 26, 2019 - Abstract #SOHO2019SOHO_284;
Notable in both the Alliance and Illuminate studies was a high rate of grade 5 adverse events during the ibrutinib treatment period, at 7% on both ibrutinib arms in the Alliance study (vs 1% for BR) and 10 fatal events in 113 patients on Illuminate (vs 3 events on chlorambucil-obinutuzumab)...The ASCEND trial compared acalabrutinib, a second generation, more specific covalent BTKi, to investigator choice of idelalisib rituximab or BR in relapsed CLL patients...The triple drug regimen, ibrutinib venetoclax obinutuzumab, has been reported by the Ohio State group to have a 67% rate of undetectable MRD among previously untreated patients at the conclusion of 14 months of therapy...What are the mechanisms of resistance to dual BTKi-BCL2i therapy and can we avoid resistance by stopping therapy? These are exciting times in CLL, with ever more emerging data, yet still many more questions than answers as we try to rationally integrate novel therapies into the treatment paradigm.
- Rituxan (rituximab) / Roche, Biogen, Yervoy (ipilimumab) / Ono Pharma, BMS
Marginal Zone Lymphomas () - Sep 26, 2019 - Abstract #SOHO2019SOHO_280;
Hence, also given the different size and design of these two studies, the direct comparison of their results should be taken with caution.The MALT-IPI Prognostic Index There are no widely accepted prognostic indices for MALT lymphoma...Rituximab combined with chemotherapy is the backbone treatment. Ibrutinib may be a treatment option in patients with short remissions after rituximab containing immuno-chemotheraphy.8 In the HCV-infected patients not needing immediate lymphoma treatment, antiviral treatment may induce remissions in a high proportion of case.12Selected
- Leukeran (chlorambucil) / GSK, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Hakko Kirin, Mitsubishi Tanabe
CONSIDERATIONS FOR CHYLOTHORAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 3) - Sep 25, 2019 - Abstract #CHEST2019CHEST_2590;
Ibrutinib may be a treatment option in patients with short remissions after rituximab containing immuno-chemotheraphy.8 In the HCV-infected patients not needing immediate lymphoma treatment, antiviral treatment may induce remissions in a high proportion of case.12Selected Intrapleural alteplase and DNAse were instilled for 6 doses in attempt to reexpand the lung...Low fat diet, octreotide, chlorambucil and prednisone were initiated...High suspicion for chylothorax must be maintained in CLL patients with pleural effusion to avoid delaying directed intervention.
- | Leukeran (chlorambucil) / GSK
Journal: Bifunctional peptide hybrids targeting the matrix of mitochondria. (Pubmed Central) - Sep 22, 2019
In addition, we highlight the use of the CPP sC18 as necessary part of the hybrid construct, inducing not only cellular uptake, but likewise supporting sub-organelle uptake into the mitochondrial matrix. The herein designed cell-permeable mitochondrial targeting peptide was furthermore proven to enhance the intracellular uptake of the cytostatic drug chlorambucil, making it a powerful candidate for further studies in this important field.
- | Leukeran (chlorambucil) / GSK
Journal: Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy. (Pubmed Central) - Sep 20, 2019
In vivo tumor suppression effect and biocompatibility indicated the superiorities of PPAHC nanoprodrug. Accordingly, PPAHC provides a new approach as a ROS-responsive CHL delivery system and has a great potential for cancer therapy.
- | Leukeran (chlorambucil) / GSK
Journal: Furin substrate as a novel cell-penetrating peptide: combining a delivery vector and an inducer of cargo release. (Pubmed Central) - Sep 19, 2019
This CPP can not only deliver cargo into cells but can also be cleaved by furin in cells and release the cargo. Cell-impermeable antitumor pro-apoptotic peptide KLAKLAKKLAKLAK (KLA) and chemotherapy drug chlorambucil were chosen to be delivered by the CPP into live cancer cells and their cytotoxicity was greatly enhanced for in vivo cancer treatment.
- | Leukeran (chlorambucil) / GSK
Journal: Skin sensitizing effects of sulfur mustard and other alkylating agents in accordance to OECD guidelines. (Pubmed Central) - Sep 18, 2019
Besides SM, investigated AAs were chlorambucil (CHL), nitrogen mustard (HN3) and 2-chloroethyl ethyl sulfide (CEES)...Altogether, following OECD requirements, our results suggest the classification of all investigated substances as skin sensitizers. Finally, a tentative AOP for SM-induced skin sensitization is suggested.
- | ibrutinib / Generic mfg.
Clinical, P3 data, Journal: Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. (Pubmed Central) - Sep 14, 2019
P3
The results demonstrated that first-line ibrutinib for elderly patients with chronic lymphocytic leukemia provides sustained response and survival benefits over chemotherapy with depth of response improving over time without new toxicity concerns. This trial was registered at clinicaltrials.gov as NCT01722487 and NCT01724346.
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Biogen, Roche
Clinical, Journal: Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis. (Pubmed Central) - Sep 14, 2019
There were no AEs of grade 4 or 5. Conclusions Our data confirms that the obinutuzumab-chlorambucil combination is an effective and well-tolerated regimen in untreated CLL patients with comorbidities.
- Rituxan (rituximab) / Roche, Biogen
Incidence and outcome of chronic lymphocytic leukemia with deletion 17p: An Indian experience; challenges and opportunities (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1476;
Its incidence is 12 % in upfront cases and 25.5% in relapsed /refractory cases. Chemoimmunotherapy has dismal outcome and Ibrutinib was used in a limited number of patients because of financial constraints.
- | Ukoniq (umbralisib) / TG Therap
Trial completion, Enrollment change, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Sep 6, 2019
P1, N=19, Completed, Sponsor: TG Therapeutics, Inc.
Chemoimmunotherapy has dismal outcome and Ibrutinib was used in a limited number of patients because of financial constraints. Active, not recruiting --> Completed | N=30 --> 19
- | Calquence (acalabrutinib) / AstraZeneca
New P3 trial: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 29, 2019
P3, N=150, Not yet recruiting, Sponsor: AstraZeneca
- | Leukeran (chlorambucil) / GSK
Preclinical, Journal, IO Biomarker: Chlorambucil Cytotoxicity Reduction In Rats Through Bone Marrow, An In Vivo Study. (Pubmed Central) - Aug 28, 2019
The present study demonstrated a curative effect of BM against thecytotoxic impact of CHB. Infusion of BM after chemotherapy help to diminish the chromosomal aberration, increment mitotic index and decline the Bax/Bcl2 proportion compared with[CHB] class gather that prompts expanding the survival rate of influenced cells with chemotherapy cytotoxicity.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Frontline therapies for untreated chronic lymphoid leukemia. (Pubmed Central) - Aug 22, 2019
Frontline therapy of patients with untreated CLL appears to be shifting from chemotherapy to chemotherapy-free regimens. This review summarized latest development for frontline therapies of untreated CLL.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, ibrutinib / Generic mfg.
Clinical, P3 data, Journal, IO biomarker: Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies. (Pubmed Central) - Aug 21, 2019
CIT regimens included: fludarabine + cyclophosphamide + rituximab (CLL8, CLL10), bendamustine + rituximab (CLL10), obinutuzumab + chlorambucil and rituximab + chlorambucil (CLL11), and ofatumumab + chlorambucil (COMPLEMENT-1)...Although definitive conclusions cannot be made due to inherent limitations of cross-trial comparisons, this report suggests that ibrutinib has a favorable benefit/risk profile and may potentially eliminate the need for chemotherapy in some patients. Randomized, comparative studies are needed to support these findings.
- | Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Aug 21, 2019
P3, N=535, Active, not recruiting, Sponsor: Acerta Pharma BV
Randomized, comparative studies are needed to support these findings. Trial completion date: May 2020 --> Jul 2021
- | Calquence (acalabrutinib) / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Aug 20, 2019
P3, N=535, Active, not recruiting, Sponsor: Acerta Pharma BV
Trial completion date: May 2020 --> Jul 2021 Trial primary completion date: Dec 2019 --> Feb 2019
- Rituxan (rituximab) / Roche, Biogen
Therapy Related Myeloid Neoplasia in a Large Nation-Wide Cohort of Patients with Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) - Aug 18, 2019 - Abstract #SOHO2019SOHO_171;
Whether elderly did not develop t-MN, or clinicians misinterpreted cytopenia as CLL or treatment-related or were reluctant to pursue a proper diagnostic work-up requires further studies. A well-driven cancer registry provides opportunity for future surveillance of a seldom entity.
- | Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen
Biomarker, New P2 trial: A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment (clinicaltrials.gov) - Aug 15, 2019
P2, N=31, Recruiting, Sponsor: Deok-Hwan Yang
- | Rituxan (rituximab) / Roche, Biogen
Journal: Monoclonal B lymphocytosis and minimal change disease: a new monoclonal B-cell disorder of renal significance? (Pubmed Central) - Aug 15, 2019
To our knowledge, this is the first description of the association of MBL and MCD. This case suggests that screening for MBL may have unexpected diagnostic and therapeutic implications in patients presenting with seemingly idiopathic NS.
- | Jakafi oral (ruxolitinib) / Novartis, Incyte
Review, Journal: Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know? (Pubmed Central) - Aug 9, 2019
Lastly, we discuss emerging studies on the association between ruxolitinib and high grade B-cell lymphomas...However, it is difficult to definitely disprove an association, as large prospective, controlled studies with decades of follow-up would be needed to draw conclusions. Overall, the concept of therapy-related neoplasms remains important to the field, and mandates judicious selection and sequencing of therapies for MPN patients.